American Association for Cancer Research
Browse
capr-23-0483_supplementary_table_1_suppst1.xlsx (10.93 kB)

Supplementary Table 1 from Germline Testing Identifies Pathogenic/Likely Pathogenic Variants in Patients with Pancreatic Neuroendocrine Tumors

Download (10.93 kB)
dataset
posted on 2024-07-02, 07:40 authored by Chirayu Mohindroo, Seyda Baydogan, Parul Agarwal, Robin D. Wright, Laura R. Prakash, Maureen E. Mork, Alison P. Klein, Daniel A. Laheru, Jessica E. Maxwell, Matthew H.G. Katz, Arvind Dasari, Michael P. Kim, Jin He, Florencia McAllister, Ana De Jesus-Acosta

Supplementary Table 1: Details of each P/LP detected in the high-risk cohort along with the high-risk criteria

Funding

National Cancer Institute (NCI)

United States Department of Health and Human Services

Find out more...

Cancer Prevention and Research Institute of Texas (CPRIT)

V Foundation for Cancer Research (VFCR)

Andrew Sabin Family Foundation

Shelby-Lavine Pancreatic Scholars Program

History

ARTICLE ABSTRACT

Ten percent of pancreatic neuroendocrine tumors (pNET) are related to inherited syndromes (MEN1, MEN4, VHL, NF1, and TSC). Growing evidence suggests that clinically sporadic pNETs can also harbor germline pathogenic variants. In this study, we report the prevalence of pathologic/likely pathologic (P/LP) germline variants in a high-risk cohort and an unselected cohort. We collected clinical data of patients with pNETs seen at MD Anderson Cancer Center and Johns Hopkins Hospital. The high-risk cohort included (n = 132) patients seen at MD Anderson Cancer Center who underwent germline testing for high-risk criteria (early onset, personal or family history of cancer, and syndromic features) between 2013 and 2019. The unselected cohort included (n = 106) patients seen at Johns Hopkins Hospital who underwent germline testing following their diagnosis of pNETs between 2020 and 2022. In the high-risk cohort (n = 132), 33% (n = 44) had P/LP variants. The majority of the patients had P/LP variants in MEN1 56% (n = 25), followed by DNA repair pathways 18% (n = 8), and 7% (n = 3) in MSH2 (Lynch syndrome). Patients with P/LP were younger (45 vs. 50 years; P = 0.002). In the unselected cohort (n = 106), 21% (n = 22) had P/LP. The majority were noted in DNA repair pathways 40% (n = 9) and MEN1 36% (n = 8). Multifocal tumors correlated with the presence of P/LP (P = 0.0035). MEN1 germline P/LP variants correlated with younger age (40 vs. 56 years; P = 0.0012), presence of multifocal tumors (P < 0.0001), and World Health Organization grade 1 histology (P = 0.0078). P/LP variants are prevalent in patients with clinically sporadic pNET irrespective of high-risk features. The findings support upfront universal germline testing in all patients with pNET.Prevention Relevance: Here, we present germline data from the largest reported cohort of patients with pNET (n = 238), comprising both a high-risk cohort and an unselected cohort. In both cohorts, we identify a high number of P/LPs, including those in the DNA repair pathway. Our findings support universal germline testing in patients with pNET.